TCRT
Alaunos
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Low Beta
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About TCRT
Alaunos Therapeutics, Inc.
A clinical-stage oncology-focused cell therapy company
2617 Bissonnet Street, Suite 225, Houston, TX 77005
--
Alaunos Therapeutics, Inc., was founded in Delaware. The Company is a clinical-stage oncology-focused cell therapy company focused on developing T cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenes including KRAS, TP53 and EGFR. The company has all clinical and strategic collaborations with the University of Texas MD Anderson Cancer Center and the National Cancer Institute.
Company Financials
EPS
TCRT has released its 2023 Q3 earnings. EPS was reported at -0.04, versus the expected -0.03, missing expectations. The chart below visualizes how TCRT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TCRT has released its 2024 Q4 earnings report, with revenue of 4.00K, reflecting a YoY change of 300.00%, and net profit of -742.00K, showing a YoY change of 90.54%. The Sankey diagram below clearly presents TCRT’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
